|
Development and production of DNA vaccines without antibiotic resistance gene
Key words : DNA vaccine, Antibiotic resistance, DNA production
Consortium
- Companies : Delphi Genetics SA (coordinator), Eurogentec
- Research centers : Ulg (Laboratory of Immunology-vaccinology), UCL (Unit of galenic pharmacy)
Topic of the project
Today vaccination is an uncontested way of fighting disease. DNA vaccination seems to be a particularly promising method at this time. For this application, plasmid DNA is injected into the subject (man or animal). This plasmid DNA encodes for an antigen that will be produced by the subject’s cells. In addition to the antigen, the plasmid also encodes for a resistance to an antibiotic used during the construction and production of the molecule. This resistance is increasingly less tolerated by the regulatory agencies (FDA and EMA).
In the context of this project, we are proposing to replace this resistance to an antibiotic by a selection system based on bacterial genes that have already been used by Delphi Genetics for the production of proteins without an antibiotic-resistance gene.
The project’s objective is threefold:
- To develop a technology enabling DNA vaccines to be formulated quickly and without antibiotic-resistance genes.
- To obtain sufficient scientific data to constitute a file for FDA or USDA and EMA
- To proceed with at least three examples of effective DNA vaccines in the veterinary field
Budget
This is a 3 years project with a total budget of 2,6 M€
Contact
Cédric Szpirer (coordinator)
Email : cyszpirer@delphigenetics.com
Delphi Genetics SA
Web site : www.delphigenetics.com
|